Clinical Trials Browser

Phase 2 × Rhabdomyosarcoma × cixutumumab × Clear all

Fibrosarcoma, Hemangiosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

NCT00668148 2018-07-17

A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma

Phase 2 Completed

113 enrolled 13 charts

Sarcoma

Leiomyosarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Peripheral, Neuroectodermal Tumors, Primitive

NCT01055314 2017-08-29

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Phase 2 Completed

175 enrolled 13 charts

Sarcoma

Rhabdomyosarcoma, Sarcoma

NCT00831844 2015-03-30

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Phase 2 Completed

116 enrolled 8 charts

CNSEndocrineGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Hepatoblastoma, Adrenocortical Carcinoma

Clinical Trials

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors